Y-mAbs Therapeutics

BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
Thu, 02/16/23 - 11:18 am
layoffs
Grifols
Frequency Therapeutics
Eliem Therapeutics
Aligos Therapeutics
Thermo Fisher Scientific
Magenta Therapeutics
Eisai
Amgen
Y-mAbs Therapeutics
Century Therapeutics
Elevation Oncology
Calithera Biosciences
Editas Medicine
Verily
Abzena
Y-mAbs' rare disease drug roundly rejected by FDA AdComm over weakness of single-arm trial
Fierce Biotech
Mon, 10/31/22 - 10:27 am
Y-mAbs Therapeutics
FDA
omburtamab
pediatric neuroblastoma
FDA Guidance Raises Concerns about Y-mAbs’ Neuroblastoma Treatment before Adcomm
BioSpace
Thu, 10/27/22 - 10:59 am
FDA
Y-mAbs Therapeutics
neuroblastoma
omburtamab
Go or no go? GSK takes its turn with a novel anemia class
EP Vantage
Fri, 09/30/22 - 10:52 am
FDA
GSK
Amicus Therapeutics
AstraZeneca
Novartis
Supernus
JNJ
Ipsen
Y-mAbs Therapeutics
Y-mAbs' longtime CEO steps down abruptly as FDA reviews second pediatric cancer drug
Endpoints
Thu, 04/28/22 - 11:01 am
Y-mAbs Therapeutics
Pharma CEOs
FDA
Claus Moller
Y-mAbs pushes back re-submission of its neuroblastoma BLA to end of 2021
Endpoints
Wed, 06/23/21 - 10:41 am
Y-mAbs Therapeutics
neuroblastoma
FDA
omburtamab
Regulatory progress for two biotechs stalls as FDA requests more information
MedCity News
Wed, 04/21/21 - 10:30 am
KalVista
Y-mAbs Therapeutics
FDA
KVD824
HAE
Corporate and regulatory developments over the holidays
EP Vantage
Mon, 01/4/21 - 10:20 am
AstraZeneca
Bristol-Myers Squibb
Celltrion
Cullinan Oncology
JNJ
Myovant Sciences
Osmotica Pharmaceuticals
Pfizer
Y-mAbs Therapeutics
United Therapeutics
Zai Lab